表紙
市場調查報告書

皮膚肌炎:開發中產品分析

Dermatomyositis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 361637
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
皮膚肌炎:開發中產品分析 Dermatomyositis - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 165 Pages
簡介

皮膚肌炎是一種罕見的炎症性疾病,其特徵在於伴有肌肉無力的慢性肌肉發炎。皮肌炎的症狀包括獨特的皮疹,肌肉無力和發炎性肌病,或引起肌肉發炎。危險因素包括年齡和性別。治療可採用皮質類固醇。

本報告提供皮膚肌炎治療藥的開發情形相關調查,提供開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

皮膚肌炎概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

皮膚肌炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發皮膚肌炎治療藥的企業

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Hope Pharmaceuticals Inc
  • Idera Pharmaceuticals Inc
  • KPI Therapeutics Inc
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Neovacs SA
  • Novartis AG
  • Octapharma AG
  • Pfizer Inc

藥物簡介

皮膚肌炎:暫停中的計劃

皮膚肌炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11690IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 4, 3, 2, 1 and 1 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Dermatomyositis - Overview
  • Dermatomyositis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Dermatomyositis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Dermatomyositis - Companies Involved in Therapeutics Development
  • Biocon Ltd
  • Bristol-Myers Squibb Co
  • Chugai Pharmaceutical Co Ltd
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • Eli Lilly and Co
  • GNI Group Ltd
  • Hope Pharmaceuticals Inc
  • Johnson & Johnson
  • Kezar Life Sciences Inc
  • Neovacs SA
  • NovelMed Therapeutics Inc
  • Octapharma AG
  • Pfizer Inc
  • ReveraGen BioPharma Inc
  • Viela Bio Inc
  • Dermatomyositis - Drug Profiles
  • abatacept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • baricitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BVX-20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KZR-616 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lenabasum - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies for Dermatomyositis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06823859 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pirfenidone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sodium thiosulfate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tocilizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tofacitinib citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tofacitinib citrate ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ustekinumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vamorolone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VIB-7734 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Dermatomyositis - Dormant Projects
  • Dermatomyositis - Discontinued Products
  • Dermatomyositis - Product Development Milestones
  • Featured News & Press Releases
  • Jun 12, 2019: Lenabasum open-label extension data to be presented at EULAR 2019 continue to show a favorable safety profile and improvement in efficacy outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
  • Apr 01, 2019: Neovacs announces an agreement with Biosyn to diversify its supply of Keyhole Limpet Hemocyanin
  • Dec 18, 2018: Corbus Pharmaceuticals announces Issuance of Composition of Matter Patent related to Lenabasum
  • Dec 17, 2018: Corbus Pharmaceuticals initiates "DETERMINE" phase 3 study in Dermatomyositis
  • Sep 20, 2018: Corbus Pharmaceuticals provides update on Lenabasum
  • Jul 25, 2018: Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
  • Jul 20, 2018: Corbus Pharmaceuticals receives FDA Orphan Drug Designation for Lenabasum for the treatment of Dermatomyositis
  • Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD
  • Apr 26, 2018: Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
  • Mar 02, 2018: Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
  • Feb 06, 2018: Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
  • Nov 27, 2017: Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
  • Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases
  • Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
  • Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Dermatomyositis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Dermatomyositis - Pipeline by Biocon Ltd, H2 2019
  • Dermatomyositis - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Dermatomyositis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
  • Dermatomyositis - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
  • Dermatomyositis - Pipeline by CSL Ltd, H2 2019
  • Dermatomyositis - Pipeline by Eli Lilly and Co, H2 2019
  • Dermatomyositis - Pipeline by GNI Group Ltd, H2 2019
  • Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H2 2019
  • Dermatomyositis - Pipeline by Johnson & Johnson, H2 2019
  • Dermatomyositis - Pipeline by Kezar Life Sciences Inc, H2 2019
  • Dermatomyositis - Pipeline by Neovacs SA, H2 2019
  • Dermatomyositis - Pipeline by NovelMed Therapeutics Inc, H2 2019
  • Dermatomyositis - Pipeline by Octapharma AG, H2 2019
  • Dermatomyositis - Pipeline by Pfizer Inc, H2 2019
  • Dermatomyositis - Pipeline by ReveraGen BioPharma Inc, H2 2019
  • Dermatomyositis - Pipeline by Viela Bio Inc, H2 2019
  • Dermatomyositis - Dormant Projects, H2 2019
  • Dermatomyositis - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Dermatomyositis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top